Navigation Links
Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured''

CV; the remaining eight patients tested positive for HCV, at an average of two years following the completion of treatment. The study found that these eight patients exhibited no consistency in age, gender or HCV genotype, and it has not been determined if these patients experienced a relapse or if they were re-infected with HCV.

"We at Roche are proud to be able to offer some hepatitis C patients the prospect of such a positive outcome with our currently-available therapies, but we also recognize the urgent need to further improve response rates," said Tom Klein, Vice President, Hepatology, Roche. "In addition to ongoing research with PEGASYS, Roche has the most comprehensive pipeline in the area, with four compounds currently in human development that target the virus in a number of different ways. The development of R1626 and partnerships with InterMune, Maxygen and Pharmasset, all underscore our long-term commitment to finding effective new therapies with the goal of successfully treating more patients with chronic hepatitis C."

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS, are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... PARSIPPANY, N.J. , Aug. 3, 2015  LEO ... and Drug Administration (FDA) to include psoriasis as one ... Focused Drug Development Initiative i .  Psoriasis is an ... lives and subsequent comorbidities, affecting 7.5 million people in ... of LEO Pharma,s ongoing commitment to supporting patients living ...
(Date:8/3/2015)... N.Y. , Aug. 3, 2015 ... Wilmot Cancer Institute to the OmniSeq SM ... Roswell Park Cancer Institute (RPCI) and announced it ... that support a physician-driven, collaborative approach to genomic ... outcomes.  Wilmot Cancer Institute is a rapidly expanding, ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... Researchers at Brigham and Women,s,Hospital found that patients taking ... effects were unrelated to relief from their pain,symptoms. ... examine the addictive,potential of this class of pain medicine, ... 25th Annual Meeting. , In ...
... Lethal ,Super, Strains of C.difficileCHICAGO, Jan. 28 ... scientists at The University of Nottingham are leading a ... one of the most lethal strains of hospital acquired ... technology developed in Nottingham to study the function of ...
Cached Medicine Technology:Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 3
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is worth a thousand ... and medical art can be essential. StayWell, a health solutions company, announced today it ... solutions have been used by physicians and other health care providers for more than ...
(Date:8/4/2015)... ... August 04, 2015 , ... SanusEO, the healthcare ... joins its executive leadership team as Senior Vice President of Sales and Marketing. ... and expanding global markets with a special emphasis on the healthcare industry. , ...
(Date:8/4/2015)... ... August 04, 2015 , ... Providigm, LLC, a developer of ... announced details of the Advanced level of their national accreditation for Quality Assurance ... Accreditation program , introduced in 2013, is based on standards for excellence in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Data2Life , a ... designed to provide pharmaceutical and healthcare organizations with advanced intelligence on drug effects. ... from regulatory filings (including the FDA and HealthCanada), social media and anonymized clinical ...
(Date:8/4/2015)... Ill. (PRWEB) , ... August 04, 2015 , ... ... and the specialty in which the physician is board-certified is increasingly influential in ... for Dermatologic Surgery. , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures ...
Breaking Medicine News(10 mins):Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 2Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... ... to our heroic veterans. , ... (PRWEB) May 25, 2010 -- Memorial Day weekend we celebrate the lives of countless heroes who ... “Our goal is to take it one step further than attending parades and barbeque,s, we want ...
... variants make it more likely babies will acquire the ... News) -- New research suggests that a genetic variation ... virus that causes AIDS, from their HIV-infected mothers at ... Padova, Italy, and colleagues studied 300 children born to ...
... For ... out of it! SnapComms Tools, an interactive suite of innovative employee communications tools, ... ... of Canada,s top internal communications companies, is now Canada,s exclusive reseller of SnapComms employee ...
... ... with Teva! Enter to win a complete outdoor package, valued at over $2,000: a kayak, a ... ... the season of water sandals and offer the chance to win a prize package—including a kayak, ...
... , ... Beacon Hill Village will participate in the first-ever virtual classroom presentation of Mindfulness and Chocolate. ... the Internet, will conduct the two-hour session. The class is designed to raise a ... , ...
... ... Home Appliance Group,s Protos Stove to local communities living near its Jatropha plantations in ... fuel the stoves. , ... (PRWEB) May 25, 2010 -- Indonesia based PT Waterland International has recently ...
Cached Medicine News:Health News:BuyDirectUSA.com Launches 'Operation Honor a Veteran' 2Health News:The Hoppen Group Announces Partnership with SnapComms Tools 2Health News:The Hoppen Group Announces Partnership with SnapComms Tools 3Health News:Onlineshoes.com and Teva Pair Up for $2,000 Gear Giveaway May 25-June 7 2Health News:Onlineshoes.com and Teva Pair Up for $2,000 Gear Giveaway May 25-June 7 3Health News:eMindful Provides a New Twist on Chocolate for Members of Boston's Beacon Hill Village 2Health News:Waterland International Together with Bosch and Siemens Home Appliance Group (BSH) Continue to Help Local Communities in Indonesia 2Health News:Waterland International Together with Bosch and Siemens Home Appliance Group (BSH) Continue to Help Local Communities in Indonesia 3
... The Ray TFC Unite Device is the ... The Ray TFC Unite device features the same ... contact offered by fenestrations is paramount in the ... the Ray TFC Unite system promotes load sharing ...
... The INTER FIX and ... Devices are designed to maximize ... of the implant. Both the ... RP Threaded Fusion devices combine ...
... Confirmatory (Western Blot): The Genetic Systems HIV-1 ... for the detection of antibodies to HIV-1. The ... of HIV-1 grown in the CEM cell line. ... devoid of HLA Class ll antigens, helps reduce ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
Medicine Products: